888327-36-4Relevant articles and documents
Preparation method of 2-bromo-5-(trifluoromethoxy)pyridine
-
Paragraph 0061; 0073-0076; 0088-0090, (2022/01/12)
The invention discloses a preparation method of 2-bromine-5-(trifluoromethoxy)pyridine, which comprises the following steps: reacting 2-bromo-5-hydroxypyridine (compound 1) with ethyl difluorobromoacetate (compound 1A) in the presence of organic alkali to generate a compound 2; carrying out ester group hydrolysis reaction on the compound 2 in the presence of an alkaline reagent to generate a compound 3; carrying out acylating chlorination on carboxyl of the compound 3 and oxalyl chloride under the catalysis of N,N-dimethylformamide, concentrating reaction liquid, and dropwise adding the concentrated reaction liquid and 2,2'-azodiisobutyronitrile (AIBN) into a bromotrichloromethane solution of 2-mercaptopyridine nitrogen oxide sodium salt (compound 3A) to obtain a compound 4; and dropwise adding a silver tetrafluoroborate solution into the solution of the compound 4, and conducting reacting to generate the final product 2-bromo-5-(trifluoromethoxy)pyridine. The method has the advantages of environment-friendly and easily available raw materials, mild conditions, easiness in operation, suitability for kilogram-level production and the like.
Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
-
Paragraph 0631, (2015/11/16)
In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.
METHOD FOR THE PREPARATION OF FUNCTIONALIZED TRIHALOMETHOXY SUBSTITUTED PYRIDINES
-
Page/Page column 38-39, (2010/04/28)
The present invention pertains to a process for the preparation of functionalized trihalomethoxypyridines of formula (I) comprising reacting hydroxypyridines with thiophosgene in the presence of a base; reacting the obtained chlorothionoformiates with elemental chlorine and finally converting trichloromethoxy pyridines to trihalomethoxy pyridines using a fluoride source.
A general approach to (trifluoromethoxy)pyridines: First X-ray structure determinations and quantum chemistry studies
Manteau, Baptiste,Genix, Pierre,Brelot, Lydia,Vors, Jean-Pierre,Pazenok, Sergiy,Giornal, Florence,Leuenberger, Charlotte,Leroux, Frederic R.
experimental part, p. 6043 - 6066 (2011/02/26)
The previously unknown 2-, 3-, and 4-(trifluoromethoxy)pyridines have now become readily accessible by means of an efficient and straightforward large-scale synthesis. Their regioselective functionalization by organometallic methods has been studied and has afforded new and highly important building blocks for life-sciences-oriented research. In addition, the first X-ray crystallographic structure determinations of (trifluoromethoxy)pyridines have been performed. Lowest-energy conformations of (trifluoromethoxy)pyridines and (trifluoromethoxy)pyridinium cations were determined by in silico studies. A general and efficient route to (trifluoromethoxy)pyridines is reported. Regioselective functionalization by organometallic methods afforded new and highly important building blocks for life-sciences-oriented research. The first X-ray crystallographic structure determinations of (trifluoromethoxy)pyridines have been performed and supported by in silico studies.
SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
-
, (2015/10/07)
Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.